Applications of 5-[2-Cyclopropyl-1-(2-Fluorophenyl)-2-Oxoethyl]-5,6,7,7A-Tetrahydrothieno[3,2-C]Pyridin-2(4H)-One in Industrial Manufacturing

As a specialized chemical raw material manufacturer, we supply 5-[2-Cyclopropyl-1-(2-Fluorophenyl)-2-Oxoethyl]-5,6,7,7A-Tetrahydrothieno[3,2-C]Pyridin-2(4H)-One to process-intensive industries demanding high-purity components for intricate synthesis. The following application sectors leverage our product at distinct production stages for the development of advanced chemical goods meeting rigorous industry criteria.

1. Pharmaceutical Intermediates for Antithrombotic Drug Synthesis

Large-scale pharmaceutical facilities utilize this raw material as a protected intermediate in the route to synthesize antithrombotic agents. Its structural motif supports the targeted assembly of pyridinone-containing active pharmaceutical ingredients (APIs), especially in manufacturing direct Factor Xa inhibitors. Integration into the synthetic process requires close management of chemical purity and trace impurity levels for final regulatory approval. Facilities source our material for controlled batch production where strict traceability and documentation back up every lot.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice (GMP) for APIs
• USP & EP (United States Pharmacopeia, European Pharmacopoeia) monograph guidance for intermediates
• US FDA 21 CFR Part 210/211
• EU Directive 2001/83/EC

Typical usage ratio

• 0.8–1.2 molar equivalents per batch, carefully adjusted based on downstream synthesis yield optimization and impurity management

Downstream process integration

• Step-wise introduction as a protected intermediate following initial fluorination, prior to cyclization and final saponification/hydrolysis steps

Final product types

• Direct oral anticoagulant drug substances (e.g., edoxaban precursor)
• Registered pharmaceutical grade intermediates

2. Fine Chemical Building Block for Agrochemical Research

Contract research organizations and agrochemical developers select this advanced heterocycle to construct new lead compounds for herbicidal and fungicidal applications. The cyclopropyl-fluorophenyl arrangement enables structure-activity relationship (SAR) studies by medicinal chemistry teams, driving new patentable agrochemical candidates. Synthetic chemists demand batch consistency as they develop both scalable processes and analytical methods for subsequent registration testing.

Industry compliance standards

• OECD GLP (Good Laboratory Practice) for chemical research
• ECHA REACH Annexes VII–X for substance evaluation and registration
• ISO 9001:2015 Quality Management for Analytical Reference Substances
• CropLife International guidance for active ingredient development

Typical usage ratio

• 0.5–1.5 equivalents depending on the library scale and synthetic pathway explored in micro to pilot plant settings

Downstream process integration

• Incorporated during the hit-to-lead optimization stage before functional group derivatization and formulation screening

Final product types

• Screening libraries for bioassay evaluation
• Isolated lead candidate molecules for further toxicology and efficacy studies

3. Custom Intermediate for Specialty API CDMO Projects

Leading contract development and manufacturing organizations (CDMOs) apply this molecule as a tailored intermediate in multi-step synthesis for custom API projects. Clients demand batch-specific documentation and scalable processing methods optimized for downstream conversion and regulatory submission. This raw material enters diverse custom protocols depending on each project’s structure-activity and impurity profile requirements. Full analytical profiles provided by our site support robust project audits and process transfer.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• Chinese Pharmacopoeia ChP General Chapters application for registered intermediates
• GMP certification with full traceability under ISO 13485 (if supplied for cGMP projects)
• Project-specific customer audit protocols aligned with EMA or FDA expectations

Typical usage ratio

• 1.0–2.0 equivalents per reaction step, adjusted by chemical route efficiency and impurity tolerance for regulatory compliance

Downstream process integration

• Inserted in key carbon skeleton elongation or ring-forming transformations within custom synthetic routes developed for NDA or ANDA submissions

Final product types

• Advanced API precursors for Phase I–III clinical development
• Specialty pharmaceutical intermediates designated for market authorization dossiers

4. Reference Standard Preparation for Analytical Method Development

Analytical laboratories and in-house QC departments use high-purity grades of this compound to prepare analytical reference standards. Labs require exact characterization to validate quantification methods for both development and release testing of finished pharmaceutical and chemical goods. Trace level impurity guidance and stability data provided at dispatch ensure compliance for each batch, allowing robust system suitability testing during daily operations.

Industry compliance standards

• Ph. Eur. 2.2.24 (HPLC systems suitability)
• USP Chapter <1225> Validation of Compendial Procedures
• ISO/IEC 17025:2017 General requirements for testing laboratories
• FDA guidance for industry: Analytical Procedures and Methods Validation

Typical usage ratio

• 1–10 mg per independent reference solution, quantity specified by calibration curve and LOD/LOQ determination requirements

Downstream process integration

• Dissolved in acetonitrile, methanol, or buffer as standard solutions to calibrate equipment for in-process controls and release testing

Final product types

• HPLC/GC/MS analytical reference standards for pharmaceutical QC
• System suitability and impurity quantification kits for regulatory submissions